Linda Stein Gold, MD

A 5-expert panel continues their conversation on atopic dermatitis, discussing patient-centered care and key takeaways.

A 5-expert panel continues their conversation on atopic dermatitis, exploring beyond steroids and addressing unmet needs.

A 5-expert panel delves into atopic dermatitis guidelines and recommendations and recent studies to make note of.

Dr Linda Stein Gold and Dr Michael Cameron assess the safety and tolerability of topical ruxolitinib cream, offering guidance on counseling patients about the black box warning. They also address the perception of limited treatment access and strategies for overcoming this barrier.

Experts in dermatology review the rapid itch relief provided by topical ruxolitinib cream and attribute its fast-acting efficacy to its mechanism of action targeting a variety of interleukins.

Linda Stein Gold, MD, and Michael Cameron, MD, FAAD, discuss the need for non-steroidal treatment options in atopic dermatitis management, driven by patient preferences. They highlight the challenges with previous oily options, which often caused tolerability and irritation issues, and how the approval of ruxolitinib cream addresses these concerns.

A panel of experts discusses tailoring treatment to patient needs, supporting patients' mental health, and considering future directions.

A panel of experts discusses unique needs of patients with skin of color, look at long-term safety and efficacy of emerging oral treatments, and delve into combining topicals with systemic therapies.

A panel of experts discuss navigating regimen complexity, patient-friendly adherence strategies, addressing steroid phobia and attitudes, and dive into current treatment guidelines.

Experts in dermatology delve into patient communication regarding treatment expectations, emphasizing the significance of ongoing follow-up and maintenance practices. They also address the safety, tolerability, and comfortability aspects associated with the use of this novel TYK-2 inhibitor, drawing insights from long-term clinical trial data.

Linda Stein-Gold, MD, Mona Shahriari, MD, and Micheal Cameron, MD, FAAD explore emerging oral treatments for the management of plaque psoriasis, emphasizing the novelty of TYK-2 inhibition. They discuss the unique POETYK trial design, stressing the importance of the inclusion of an active control arm. Lastly, they highlight the clinical efficacy of this novel treatment MOA.

Linda Stein Gold, MD, reviewed recent studies of various topical retinoids and their ability to decrease atrophic scars during the 2023 ARM Yourself With Knowledge webinar.

Experts discuss enhancing patient outcomes, comparing clobetasol cream concentrations, and more.

Experts discuss enhancing patient outcomes, topical formulations and epidermal barrier dysfunction, and more.

Experts discuss enhancing patient outcomes, the "mounting mutiny" against topicals, and more.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, share their approaches to educating patients on use of steroids for dermatologic conditions, highlighting how they approach pediatric patient populations.

Experts in dermatology discuss the benefits of improved topical steroidal vehicle excipients and their impact on treatment duration and response.

Linda F. Stein Gold, MD; Jayme M. Heim, MSN, FNP-BC; and Darren West, MPAS, PA-C, review the adverse effect profiles of steroidal and nonsteroidal treatments, focusing on hypothalamic pituitary adrenal axis suppression.

Darren West, MPAS, PA-C; and Jayme M. Heim, MSN, FNP-BC, comment on how steroids continue to fit into the topical treatment armamentarium.

In the final part of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 3 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 2 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

In part 1 of this Frontline Forum series, Neal Bhatia, MD; Dawn Eichenfield, MD, PhD; Lawrence Eichenfield, MD; Linda F. Stein Gold, MD; and Guy Webster, MD, PhD, discuss the practical and clinical considerations in the management of acne vulgaris, reviewing available treatment options and how to treat acne scars.

Stein Gold reviewed biologics and JAK inhibitors for AD at Fall Clinical for PAs and NPs, as well as topical and oral agents for tough acne.

A plethora of oral and topical treatments are available for patients, according to Stein Gold’s SCALE 2023 sessions.

Experts in dermatology review the dosing and meal requirements need with isotretinoin administration, highlighting the impact and benefit of the novel lidose and micronized formulations.

Linda Stein-Gold, MD and Neal Bhatia, MD discuss their approach to acne management highlighting the novel utility of clascoterone cream 1% and where this fits into their treatment regimens.

Experts describe roflumilast patient selection for plaque psoriasis treatment.

Linda Stein Gold, MD, and Jennifer Soung, MD, discuss real world experience of using roflumilast for plaque psoriasis therapy.

Jennifer Soung, MD, review long term data for tapinarof for the treatment of plaque psoriasis.